- Home
- ACIU vs AWP Comparison
ACIU vs AWP Comparison
Compare ACIU & AWP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- AWP
- Stock Information
- Founded
- ACIU 2003
- AWP 2007
- Country
- ACIU Switzerland
- AWP United States
- Employees
- ACIU N/A
- AWP N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- AWP Trusts Except Educational Religious and Charitable
- Sector
- ACIU Health Care
- AWP Finance
- Exchange
- ACIU Nasdaq
- AWP Nasdaq
- Market Cap
- ACIU 332.4M
- AWP 352.4M
- IPO Year
- ACIU 2016
- AWP N/A
- Fundamental
- Price
- ACIU $2.68
- AWP $3.92
- Analyst Decision
- ACIU Strong Buy
- AWP
- Analyst Count
- ACIU 2
- AWP 0
- Target Price
- ACIU $12.00
- AWP N/A
- AVG Volume (30 Days)
- ACIU 134.5K
- AWP 331.5K
- Earning Date
- ACIU 11-05-2024
- AWP 01-01-0001
- Dividend Yield
- ACIU N/A
- AWP 12.48%
- EPS Growth
- ACIU N/A
- AWP N/A
- EPS
- ACIU N/A
- AWP N/A
- Revenue
- ACIU $48,505,404.00
- AWP N/A
- Revenue This Year
- ACIU $85.33
- AWP N/A
- Revenue Next Year
- ACIU $80.69
- AWP N/A
- P/E Ratio
- ACIU N/A
- AWP N/A
- Revenue Growth
- ACIU 4097200.00
- AWP N/A
- 52 Week Low
- ACIU $2.25
- AWP $3.06
- 52 Week High
- ACIU $5.14
- AWP $4.20
- Technical
- Relative Strength Index (RSI)
- ACIU 27.49
- AWP 31.95
- Support Level
- ACIU $2.62
- AWP $3.80
- Resistance Level
- ACIU $3.02
- AWP $4.43
- Average True Range (ATR)
- ACIU 0.13
- AWP 0.08
- MACD
- ACIU -0.05
- AWP -0.04
- Stochastic Oscillator
- ACIU 9.52
- AWP 20.69
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About AWP abrdn Global Premier Properties Fund of Beneficial Interest
Aberdeen Global Premier Properties Fund is a diversified, closed-end management investment company. Its objective is to seek high current income and capital appreciation. It predominantly invests in equity and debt securities of domestic and foreign issuers which are principally engaged in the real estate industry, real estate financing or control real estate assets. Its portfolio of investments consists securities of Industrial REITs, Retail REITs, Data Center REITs, Health Care REITs and others.